Diagnostic Power of Selected Cytokines, MMPs and TIMPs in Ovarian Cancer Patients – ROC Analysis

The aim of the study was to identify new non-invasive ovarian cancer (OC) tumor markers. In postmenopausal ovarian cancer patients and in a control group (benign ovarian lesions and healthy subjects), preoperative plasma levels of cytokines, metalloproteinases and their tissue inhibitors were determ...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 39; no. 5; pp. 2575 - 2582
Main Authors BĘDKOWSKA, GRAŻYNA EWA, PISKÓR, BARBARA, GACUTA, EWA, ZAJKOWSKA, MONIKA, OSADA, JOANNA, SZMITKOWSKI, MACIEJ, DĄBROWSKA, MILENA, ŁAWICKI, SŁAWOMIR
Format Journal Article
LanguageEnglish
Published Greece International Institute of Anticancer Research 01.05.2019
Subjects
Online AccessGet full text
ISSN0250-7005
1791-7530
1791-7530
DOI10.21873/anticanres.13380

Cover

More Information
Summary:The aim of the study was to identify new non-invasive ovarian cancer (OC) tumor markers. In postmenopausal ovarian cancer patients and in a control group (benign ovarian lesions and healthy subjects), preoperative plasma levels of cytokines, metalloproteinases and their tissue inhibitors were determined using ELISA while those of CA125 and HE4 by chemiluminescent microparticle immunoassay methods. The diagnostic sensitivity (SE) value was the highest for HE4 and MMP-7 (78.0%). The diagnostic specificity (SP) for M-CSF, VEGF and MMP-9 was 95.2%, 95.2% and 95.7%, respectively. The highest positive predictive value (PPV) for M-CSF and MMP-9 was ~84.6% and negative predictive value (NPV) for MMP-7 and HE4 was ~87.6%. The biggest areas under the ROC curve were obtained for the combination of VEGF, MMP-7 or MMP-9 with HE4+CA125 (0.9130-0.9234), but not for CA125+HE4 (0.8260). Our research confirms the validity of combining classic markers with new markers to improve the diagnostic power of CA125 and HE4.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0250-7005
1791-7530
1791-7530
DOI:10.21873/anticanres.13380